Reduced LPA expression after peroxisome proliferator-activated receptor alpha (PPARalpha) activation in LPA-YAC transgenic mice

Päivi A Teivainen-Laedre; Knut A Eliassen; Marit Sletten; Adrian J Smith; Kåre Berg

doi:10.1016/j.pathophys.2004.12.002

Reduced LPA expression after peroxisome proliferator-activated receptor alpha (PPARalpha) activation in LPA-YAC transgenic mice

Pathophysiology. 2005 May;11(4):201-208. doi: 10.1016/j.pathophys.2004.12.002.

Authors

Päivi A Teivainen-Laedre¹, Knut A Eliassen, Marit Sletten, Adrian J Smith, Kåre Berg

Affiliation

¹ Institute of Medical Genetics, University of Oslo, P.O. Box 1036, Blindern, NO-0315 Oslo, Norway; Department of Medical Genetics, Ullevål University Hospital, Oslo, Norway.

PMID: 15837165
DOI: 10.1016/j.pathophys.2004.12.002

Abstract

BACKGROUND:: Apolipoprotein(a) (apo(a)), which is part of the atherogenic lipoprotein Lp(a), shares structural homology with plasminogen (plg). Genes coding for plasminogen (PLG) and apo(a) (LPA) are linked and situated 40kb apart in the telomeric region of the long arm of chromosome 6. LPA is naturally expressed only in primates and hedgehogs. Thus, access to knowledge regarding the mechanism by which LPA expression is regulated is limited due to shortage of appropriate animal models. However, mice transgenic for the human LPA gene have been produced. Lp(a) levels in man are genetically determined and not altered significantly by dietary changes. In contrast, mice transgenic for LPA-yeast artificial chromosome (LPA-YAC) have markedly reduced apo(a) levels after maintenance on a high-fat diet. LPA-YAC carries the 40kb LPA-PLG intergenic region, which includes a putative binding site for peroxisome proliferator-activated receptor alpha (PPARalpha). Therefore, we examined if fibrates, which exert their effect via PPARalpha, could alter LPA expression in transgenic mice. METHODS:: Two LPA transgenic mouse lines with or without the LPA-PLG intergenic region we fed either PPARalpha agonist fenofibrate (FF) or 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY 14643) containing diets for 3 weeks. For the study of serum apo(a) levels, blood were sampled prior the experiment and when the animals were sacrificed. For the study of gene expression pattern pieces of livers were collected and submerged in RNAlater buffer and stored at -70 degrees C until analysis by quantitative PCR. RESULTS AND CONCLUSIONS:: The results showed that fibrates reduce LPA expression in LPA-YAC transgenic mice, but have no impact on hepatic apo(a) mRNA or serum apo(a) protein levels in LPA-cDNA transgenic mice, which lack the LPA-PLG intergenic region. This suggests that the effect of fibrates on LPA expression is mediated upstream of the LPA gene. However, on the basis of current data it is not possible to conclude that PPARalpha is the primary factor that represses LPA expression in LPA-YAC transgenic mice. Negative correlation between FXR and apo(a) mRNA levels, in addition to putative FXR DNA binding sequence in LPA-PLG intergenic region, suggest that it is equally likely that reduced expression of LPA could be a secondary consequence of PPARalpha activation on other genes, such as FXR.